# Allergy Therapeutics Plc Positive new clinical data with house-dust mite immunotherapy

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-plc-positive-new-clinical-data-house-dust-mite-immunotherapy/412751839
- Published: 2018-05-29T07:26:58+01:00
- Author: Giles Arbor

**Allergy Therapeutics plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated commercial biotechnology company specialising in allergy vaccines,
today announced positive new data on its wholly-owned modified house-dust mite subcutaneous
immunotherapy1. This data will be presented today at the 37th Annual Congress of
the European Academy of Allergy and Clinical Immunology (EAACI) in Munich, Germany.

The Group’s modified house-dust mite product sold as through a Named Patient Program
in Spain, is the precursor to the modified house-dust mite + MPL product currently
in Phase I, as announced in February 2017.

In this observational study conducted in 10 sites across Spain, 141 patients were
evaluated and demonstrated a 43% decrease in combined symptom medication score compared
with baseline after one year (p = <0.0001). In addition, in a subgroup of asthmatic
subjects, 16.7% of patients were observed with moderate persistent asthma at one
year compared with 50.9% at baseline (p = <0.01). No patients presented with serious
adverse events and no patients had to stop treatment due to any adverse event.

Allergy Therapeutics also presented a series of poster presentations at EAACI with
key highlights including an overview of the early-phase pre-clinical developments
for the Group’s planned recombinant peanut vaccine3 and a discussion of the results
of a non-interventional study investigating rapid up-dosing of tree sublingual immunotherapy4.

Other events held by the Group at EAACI included a satellite symposium entitled:“
Adjuvants through the ages”2 which provided a summary of how adjuvant technologies
have evolved and how Allergy Therapeutics is spearheading the design and testing
of state of the art allergen-specific immunotherapies.

> **Manuel Llobet, Allergy Therapeutics plc Chief Executive Officer, commented:**“
> We are excited to be sharing our latest research at EAACI, demonstrating the breadth
> of our unique allergen immunotherapy company. The positive new data on our modified
> house-dust mite immunotherapy and our recent announcement on the success of our
> Grass G205 dose-finding clinical study confirms that our novel allergen-specific
> immunotherapies are formulated to the optimal strength, and we believe Allergy
> Therapeutics has the potential to transform allergy treatment with optimised-dose,
> well-characterised, aluminium-free, convenient products.”

Share on:
